Is High Iron Levels a sign of Cancer: Is There a Connection between Cancer and High Iron Level?

Iron is an essential mineral which has a very crucial role to play in various physiological body functions, such as in oxygen transport, DNA synthesis, and cell division.

But studies in the recent past suggest that an overload of the body with iron or iron overload is associated with an increased cancer risk.

This leads to the question: Is high iron level a cancer sign? Although iron is critical for normal cellular processes, out-of-range levels of iron, especially high iron, have the potential to favor tumor growth and cancer development.

This paper examines the relationship between increased iron levels and cancer, including possible mechanisms, major research discoveries, and changes in iron metabolism that affect cancer growth and proliferation.

Iron is highly important for the creation of red blood cells and distribution of oxygen throughout the body.

It is also primarily stored in the liver, from which it needs to be tightly regulated through a process called iron homeostasis, so that the body of the individual has an adequate amount of iron to carry out its functions and at the same time avoids toxicity due to excessive accumulation of iron.

Iron is absorbed in the diet, and the quantity is circulated by the blood as serum iron.

However, high levels of iron could be toxic. The lack of proper regulation of iron causes oxidative stress.

In this case, the formation of ROS results in DNA, protein, or lipid damage, which eventually leads to cell death. Elevated iron levels interfere with normal cellular activity and lead to changing normal cells into cancerous cells.

This duality, in which iron is essential but at high doses can become toxically associated with cancer risk, has driven scientists to explore and discuss the role of iron in cancer risk.

Iron overload is an abnormal accumulation of excess iron within the body.

It could be genetic, as with people who have hemochromatosis, or the result of chronic overrepletion with iron.

A hypothesis has been advanced that iron overload might also be related to an increased rate for breast cancer, pancreatic cancer, and colorectal cancer.

Iron Overload causes an increase in the production of ROS, which in turn lead to oxidative stress.

Oxidative stress further leads to DNA mutations, cellular damage, and inflammation that further increases the development and progress of cancer cells.

This role of iron, which promotes DNA damage and cellular mutations, places a very significant role in the growth of cancer.

Iron Metabolism and Cancer Critical studies interfere with iron metabolism in cancer cells.

Cancer cells have high demands for iron because they are rapidly growing and dividing; therefore, iron metabolism in cancer cells has to be disrupted so that a steady supply of iron could be available and ensure survival.

This relationship is complex, as intracellular iron levels are tightly regulated by proteins involved in uptake, storage, and export of the element.

Studies have shown that levels of iron-regulating proteins, such as transferrin receptors and ferritin, are often elevated in cancer cells.

This allows cancer cells to uptake more iron from the blood and utilize it for their metabolic needs.

A higher level of iron in the tumor microenvironment encourages cancer and metastasis.

For this scenario, it was suggested that the targeting of iron metabolism might be an effective strategy in the treatment against cancer.

Iron plays a critical role in the growth and development of a tumor.

In cancer, iron supports the process of cellular proliferation. Excess iron feeds the growth of the tumor.

Another way in which iron contributes to the formation of new blood vessels, a process referred to as angiogenesis, is quite crucial when supplying the necessary growth factors to rapidly proliferating tumors for oxygen and nutrients.

Studies have shown that iron overload encourages the growth of tumor cells, particularly those cancers based diseases, such as breast cancer and colorectal cancer.

The role of iron in these cancers is associated with its stimulation of the oxidative stress or DNA damage.

Iron may facilitate the metabolic activity of cancerous cells since it can enhance the energy production of the cells.

That is, cells produce more energy through synthesizing essential elements for growth.

One of the big questions is whether elevated iron levels are a marker or an indicator of cancer.

While high iron levels alone confirm nothing, they do speak to possible underlying conditions that can predispose to cancer, especially to the occurrence of cancers, particularly those that are iron dependent.

Elevated iron occurs in conditions such as hemochromatosis where the body absorbs too much iron leading to iron overload.

In cases of iron overload, its deposition could increase the opportunities for cancers to occur, even including the liver and the pancreas, where excess iron is mainly deposited.

Iron overload in the liver has been associated with the potential for the development of pancreatic cancer and even liver cancer.

Although it must be noted that high levels of iron may increase one's chances for developing a cancer, they are not the cause.

There is a proven link between iron and cancer, and so scientists have shown interest in developing iron chelators as a therapeutic agent.

Iron chelators are chemical compounds that bind to iron for its removal from the body and might therefore lower the availability of iron to cancer cells.

The decrease in the availability of iron slows down the proliferation of cancer and induces cell death in iron-dependent tumors.

Experiments have been performed, and the results have demonstrated that iron chelators are able to inhibit tumor growth in animal models and may represent an exciting new area for the development of therapies against those cancers most dependent on iron.

However, much work will have to be carried out before iron chelators will be ready for use as agents in the clinical treatment of cancers.

For example, some researchers have identified a relationship between high iron levels and breast cancer.

In breast cancer, iron helps the cells feed the growth of a tumor by ensuring there is oxidative stress and, hence, DNA damage.

The expression of proteins that have roles on the regulation of iron is, therefore, usually increased in breast cancer cells, thus enabling them to uptake much more iron for the feeding of their growth process.

The degree of elevated iron levels in the breast cancer patients also relates to poor outcome.

Indeed, excess iron promotes cancer cells' invasion.

Some of the agents proposed are indeed iron chelators, which can depress the levels of iron in addition to inhibiting pancreatic cancer cell growth.

Another form of cancer in which iron metabolism is implicated is pancreatic cancer.

There is evidence found that ferritin determined in the liver indicates overload and is associated with a possibility of pancreatic cancer.

Thus, iron can contribute to mutations in DNA and inflammation in the pancreas, which are the risk factors for the development of pancreatic cancer.

Moreover, cancer cells derived from pancreatic cancer often have abnormal iron metabolism, which supports their survival by accumulating more iron.

Thus, targeting their iron metabolism might unveil a new avenue of treatment for this very aggressive form of pancreatic cancer.

Another associated strong condition is elevated iron levels with colorectal cancer.

According to research, people who suffer from iron overload conditions, such as hemochromatosis, are generally at a higher risk of developing colorectal cancer.

This happens because of chronic inflammation caused by excessive iron in the colon and damage of cells followed by tumor development.

Iron chelators have also been studied as a therapeutic drug in colorectal cancer, since they may be beneficial to reduce the iron concentration in colon to restrain tumor growth.

Further studies are to be performed to determine the efficacy of iron chelation therapy for the treatment of colorectal cancer patients.

The tumor microenvironment is the environment in which a tumor finds itself, including the neighboring cells, blood vessels, and immune cells.

Iron in the Tumor Microenvironment fuels cancerous progression as the tumor sequesters iron from the blood for its growth; elevated levels of iron within the microenvironment enhance the metastatic capabilities of a tumor cell and its ability to avoid the immune system.

If the tumor microenvironment iron homeostasis is kept tight, control of it by cancer cells can be disrupted to offer a novel cancer therapy strategy.

The reduction of iron metabolism and then reduction of available iron within the tumor microenviroment could hamper tumor growth and result in the benefits of the patients.

One of the critical roles in which iron is involved in cancer is through induction of oxidative stress; when iron encounters oxygen in the organism, as described above, it leads to the formation of reactive oxygen species (ROS) that damage cellular contents and can contribute to the development of cancer-inducing mutations.

Oxidative stress is generally viewed as playing a role in the pathogenesis of many cancers, and iron overload facilitates this process by increasing ROS formation.

Besides oxidant stress, iron is implicated in mechanisms leading to cell death.

The general belief that cancer cells exploit iron to prevent apoptosis, or programmed cell death, implies that it may contribute to the survival and growth of cancerous cells, given that the intracellular iron concentration in such cells is considerably high.

A high concentration of intracellular iron can suppress the normal signals that would result in cell death and thus allow survival and growth of the cells.

Future advancements in the role of iron in cancer research are going to uncover more about iron metabolism and its functions as well as impact on cancer progression. Some of the most exciting areas of future research include targeting iron homeostasis and metabolism for cancer therapy.

These iron chelators, that have previously exhibited promising results in preclinical studies, will likely be part of iron-dependent cancer treatment protocols in the near future.

Biomarkers in identifying high iron levels would assist doctors in identifying the patients at a higher risk of cancer progression or recurrence.

Monitoring and adjusting treatment based on the iron level may make a difference to the doctors in order to deliver an improved outcome for the patient dealing with cancer.

High levels of iron are indeed oncogenic. Oxidative stress, DNA damage, and tumor development during progression arise due to iron overload; it is crucial in various cancers, including breast, pancreatic, and colorectal cancers.

The role of iron is multifaceted, with its disturbances arising both in iron metabolism and within the tumor microenvironment to help maintain or allow the survival or proliferation of cancer cells.

While high levels of iron are not diagnostically independent for the presence of cancer, they may constitute an important risk factor, particularly in those suffering from such conditions as hemochromatosis.

It is thus evident that research into the metabolism of iron in cancer and the application of iron chelators to treat cancer is promising to help improve treatment and prevention of this malignancy.

* Medical Disclaimer - The following information is for educational purposes only. No information provided on this website, including text, graphic, and images, are intended as substitutes for professional medical advice. Please consult with your doctor about specific medical advice pertaining to your condition(s).